| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6da64d778e593fd180dc96d9bde35014 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-1062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-008 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-4925
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M27-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-14542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12 |
| filingDate |
2015-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6d44b7da1290592b954947996f181dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9158bdbc1e56cdc83a92c938d83b0c17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cccceaff3d5c867d7d2edac132ce9ee0 |
| publicationDate |
2017-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2015335855-A1 |
| titleOfInvention |
Method of treating patients with hepatorenal syndrome type 1 |
| abstract |
The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A patient identified as suffering from HRS-1 is tested to determine if the patient meets at least two out of three criteria, wherein the three criteria include a WBC <4 or >12 cells/µL; HR >90 bpm; and any one of HCO3 <21 mmol/L or PaCO2 <32 mmHg or > 20 breaths per minute. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce a reduction in serum creatinine of at least 1.0 mg/dL. |
| priorityDate |
2014-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |